RE:Annual Report & Annual Information Form Published Does this make sense? I am looking for validation Not cheerleading .
These additions will be complementing the regular business of the company for the first quarter. Most of them were added so they impacted the 4th quarter which was part of the record revenue for the year.
Almost 50% of the record yearly revenue was earned in the fourth quarter . The additional launches are adding enough so that the first quarter should be impacted the same way. If nothing changes they should have an excellent result .
They do not look as though they need to raise capital so they can keep buying back shares .
The first three quarters of the year should be very good for sales even if the Covid sales are no more.
The submitions that they made in 2022 should impact the last quarter of 23and lead in 24. More submissions ,I assume, will be made in 23.
Hurry up and wait ?
• Launched Lenvima®, Halaven® and Rembre® in Colombia in Q1-22.
• Entered into exclusive license and supply agreements with Rigel Pharmaceuticals to commercialize fostamatinib in
LATAM in May 2022.
• Entered into an exclusive license, distribution and supply agreement with Helsinn for AKYNZEO® oral/IV
(netupitant/palonosetron/fosnetupitant/palonosetron) in Canada, Brazil and select LATAM countries and ALOXI®
oral/IV (palonosetron) in Canada in May 2022.
• Relaunched AKYNZEO® in Canada, Brazil and Argentina, and ALOXI® oral/IV in Canada in second half of 2022.
• Submitted tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT) to ANVISA for regulatory approval in Brazil and Colombia in Q4-22 and Argentina in Q1-23.
• In-licensed three branded generics products for key territories in LATAM.
• Obtained regulatory approval for Palbocil® (palbociclib) in Argentina in Q4-22.
• Submitted two branded generic products (palbociclib and pomalidomide) for regulatory approval in Chile and Colombia
in Q4-2022.